SCHEDULE: EcoR1 Capital Discloses Stake in Alto Neuroscience

EcoR1 Capital, LLC and related entities have reported beneficial ownership of 5.8% of Alto Neuroscience, Inc. common stock following the company's recent offering.

Summary

• EcoR1 Capital, LLC, along with EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman, have filed a Schedule 13G.
• This filing indicates beneficial ownership of Alto Neuroscience, Inc. common stock.
• The total aggregate amount beneficially owned by EcoR1 Capital, LLC is 2,232,000 shares, representing 5.8% of the class.
• Oleg Nodelman also holds 2,232,000 shares, representing 5.8% of the class.
• EcoR1 Capital Fund Qualified, L.P. holds 2,065,935 shares, representing 5.3% of the class.
• The percentage calculations are based on 38,829,167 shares of Common Stock outstanding after the closing of the Issuer's offering on July 14, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating significant investor interest and confidence from a known investment firm following a recent offering.

Positives

• EcoR1 Capital has taken a significant stake in Alto Neuroscience, Inc., suggesting confidence in the company's prospects.
• The filing indicates a substantial ownership percentage (5.8%) by EcoR1 Capital, LLC and Oleg Nodelman, and 5.3% by EcoR1 Capital Fund Qualified, L.P., post-offering.

Risks

• The filing does not explicitly mention any risks.
• As a Schedule 13G filing, it primarily reports ownership and does not typically detail operational or market risks.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Management Comments

• EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman disclaim beneficial ownership of securities except to the extent of their pecuniary interest.
• EcoR1 Capital Fund Qualified, L.P. expressly disclaims membership in a group and beneficial ownership beyond its pecuniary interest.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies, particularly following offerings. This indicates active investment management within the biotechnology or healthcare sector where Alto Neuroscience operates.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can influence market perception and potentially lead to increased liquidity or volatility.
• Management: The ownership stake by EcoR1 Capital may lead to increased engagement or scrutiny from the investor.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• EcoR1 Capital will continue to hold and potentially manage its investment in Alto Neuroscience, Inc.
• Further filings may be required if ownership levels change significantly.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide operational or financial performance data. While EcoR1's investment suggests confidence, a 'hold' recommendation is appropriate without further performance metrics or strategic updates from Alto Neuroscience itself.

Keywords

Schedule 13G, Alto Neuroscience, EcoR1 Capital, Beneficial Ownership, Common Stock, SEC Filing, Investment, Oleg Nodelman